[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577301":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":10,"centralContacts":49,"locations":59,"responsibleParty":82,"collaborators":86,"id":89,"slug":10,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":10,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":10,"studyType":101,"phases":10,"briefSummary":102,"conditions":103,"keywords":109,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Seoul St. Mary's Hospital","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Advanced immunochemotherapy",null,"Relapsed\u002Frefractory high grade B cell lymphoma patients treated with either chimeric antigen receptor T cell therapy, bispecific antibody, or antibody-drug conjugate",[13,14,15],"Drug: CAR-T Therapy","Drug: Bispecific antibody","Drug: Antibody-Drug Conjugate",{"label":17,"type":10,"description":18,"interventionNames":19},"Classical Immunochemotherapy","Relapsed\u002Frefractory high grade B cell lymphoma patients treated with either proteasome inhibitor, immune modulatory drug, or monoclonal antibody.",[20,21,22],"Drug: Monoclonal antibody","Drug: Proteasome Inhibitor","Drug: IMiD treatment",[24,29,33,37,41,45],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"DRUG","CAR-T Therapy","It uses the patient's own T cells, and requires a manufacturing process to modify and expand T cells before infusion. It directly targets B cell specific antigens, such as CD19 or CD20.",[9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"Bispecific antibody","It uses a dual targeting mechanism to enhance specificity and immune activation. It is an off-the-shelf treatment, and doesn't require a manufacturing process of patient cells.",[9],{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"Antibody-Drug Conjugate","It is a targeted therapy consisting of a monoclonal antibody linked to a cytotoxic drug. The antibody binds to a specific antigen on cancer cells, delivering the cytotoxic agent directly to the tumor, minimizing systemic toxicity.",[9],{"type":25,"name":38,"description":39,"armGroupLabels":40,"otherNames":10},"Monoclonal antibody","Monoclonal antibodies are lab-engineered antibodies that target specific antigens expressed on cancer cells. These commonly target CD20 (rituximab or obinutuzumab) to mediate immune destruction.",[17],{"type":25,"name":42,"description":43,"armGroupLabels":44,"otherNames":10},"Proteasome Inhibitor","It blocks the activity of proteasomes, which role is degrading damaged proteins. This disruption induces apoptosis in cancer cells. Common agents include bortezomib and carfilzomib.",[17],{"type":25,"name":46,"description":47,"armGroupLabels":48,"otherNames":10},"IMiD treatment","Immune modulatory drugs modulate the immune response by enhancing T-cell and NK cell activty to disrupt tumor progression. Common drugs include lenalidomide and thalidomide.",[17],[50,55],{"name":51,"role":52,"phone":53,"phoneExt":10,"email":54},"Sung-Soo Park, MD. PhD.","CONTACT","+82-02-2258-6754","sspark@catholic.ac.kr",{"name":56,"role":52,"phone":57,"phoneExt":10,"email":58},"Young-Woo Jeon, MD. PhD.","+82-10-2691-4067","native47@catholic.ac.kr",[60,74],{"facility":61,"status":62,"city":63,"state":10,"zip":64,"country":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"Seoul St. Mary Hospital","RECRUITING","Seoul","06591","South Korea",{"type":67,"coordinates":68},"Point",[69,70],126.9784,37.566,{"lat":70,"lon":69},[73],{"name":51,"role":52,"phone":53,"phoneExt":10,"email":54},{"facility":75,"status":62,"city":63,"state":10,"zip":76,"country":65,"cosmosGeoPoint":77,"geoPoint":79,"contacts":80},"Yeoido St. Mary Hospital","07345",{"type":67,"coordinates":78},[69,70],{"lat":70,"lon":69},[81],{"name":56,"role":52,"phone":57,"phoneExt":10,"email":58},{"type":83,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Sung-Soo Park","professor",[87],{"name":88,"class":6},"Yeouido St. Mary's Hospital","100577301",false,"NCT06796517","Immunotherapy in Lymphoma","Risk Factor Analysis Study for the Efficacy Comparison Between Advanced Immunochemotherapy and Classical Immunochemotherapy: a Prospective Study for Relapsed\u002FRefractory Lymphoma Patients","Inclusion Criteria:\n\n* Adults aged 19 to 74 years.\n* Diagnosed with any of the following after January 2015: diffuse large B cell lymphoma, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, or Burkitt lymphoma\n* Patients who have received immunochemotherapy as treatment for relapsed\u002Frefractory lymphoma\n\nExclusion Criteria:\n\n* Patients who have progressed to acute leukemia\n* Patients who developed solid tumor during treatment\n* Patients with active infectious status (acute pneumonia, viral infection, active hepatitis B state, or active pulmonary tuberculosis etc.)","ALL","19 Years","74 Years",{"count":99,"type":100},72,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to compare the efficacy of advanced immunochemotherapy and classical immunochemotherapy in relapsed\u002Frefractory high grade B cell lymophoma patients. The main question it aims to answer is:\n\nDoes advanced immunochemotherapy, including CAR-T therapy, bispecific antibody, and antibody-drug conjugate offer superior survival outcomes than when treated with classical immunochemotherapy, such as proteasome inhibitors, immune modulatory drugs, and monoclonal antibodies?\n\nResearchers will compare patients receiving advanced immunochemotherapy with those receiving classical immunochemotherapy to determine if advanced therapies result in better survival outcomes.\n\nLaboratory findings and electronic medical records (EMR) from participants will be used to assess survival outcomes and treatment-related safety profiles.",[104,105,106,107,108],"Relapsed\u002Frefractory High Grade B Cell Lymphoma","High Grade B-cell Lymphoma","Diffuse Large B Cell Lymphoma Relapsed","Primary Mediastinal Large B-Cell Lymphoma","Burkitt Lymphoma",[110,111,112,113],"immunochemotherapy","B cell lymphoma","Relapsed","Refractory","2025-01-27",{"date":116,"type":117},"2025-01-28","ACTUAL",{"date":119,"type":117},"2024-06-26",{"date":121,"type":100},"2025-12-31",{"name":84,"class":6},2]